How to Supercharge Pharmaceutical R&D in an Outbreak Situation – PART 2

The R&D window during an outbreak is very short; in some cases, there is only a limited number of patients for experimental treatment. Pharmaceutical sponsors will struggle to complete the R&D of vaccines and treatments against global health biothreats in outbreak settings until they leverage lessons learned and decisive actions to overcome practical difficulties of R&D in an outbreak setting. In this part-2 video, I’ll explain additional key factors which led to R&D successes during the 2014-15 Ebola virus outbreak in West Africa. If you haven’t watched the part-1 video, I’ve included the link in the description below. Watch PART 1 video here    • How To Supercharge Pharmaceutical R&D Duri...   Keep watching! ** Hi, I'm Dr. Amos Ndhere! I am a medical doctor, Clinical Investigator, and Regulatory Affairs Specialist. My goal is simple: Help Pharma industry leaders to gain a sound understanding of key trends, top strategies, and tools to conduct R&D in emerging markets and deliver life-changing treatments to patients faster. Do you want to safely deliver your clinical trial in sub-Saharan Africa? Let's talk: https://www.aceresearchafrica.com/con... ** PS - Join the conversation on social!   / amosndhere     / amosndhere     / amosndhere